Respiratory Infections

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

What risks and benefits need to be considered with the return of in-person classes?

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

94% of the participants developed IgG antibodies against the virus 3 weeks after administration.

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

A meeting between developers and federal experts was inconclusive to the necessity of a third mRNA dose for COVID-19.

The announcement aligns with an FDA and CDC statement against the need for booster doses.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

New ASM data show indoor environments are associated with quick and frequent pathogen contamination of the common respiratory device.

An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.

The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.

Examining pharmacological management in COVID-19 patients with ARDS requiring antifungal therapy during extracorporeal life support.

New findings on an available 15-minute test show an approximate 81% sensitivity in detection of SARS-CoV-2.

New findings from the ASM 2021 World Microbe Forum suggest the emergency-authorized platform can capably detected the highly transmissible UK-borne variant.

Five people in 4 US states in the 20-21 influenza season contracted influenza A virus variants commonly spread among pigs, but without person-to-person spread.

Cartesian Therapeutics has created its therapy, Descartes-30, the first RNA cell therapy for acute respiratory distress syndrome (ARDS), and the company is now recruiting for a clinical trial.

Paratek’s omadacycline (Nuzyra) is granted approval for an oral-only dosing regimen in adults.